Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
GBD 2019 Stroke Collaborators
https://pubmed.ncbi.nlm.nih.gov/34487721Actively Recruiting
Age: 18Years +
All Genders
ID06121336
PRecisiOn Medicine In StrokE Study on the Evolution of Plasma Brain-Derived Tau in 100 Patients With Acute Ischemic Stroke
Led by Ludwig-Maximilians - University of Munich · Updated on 2025-09-04
100
Participants Needed
1
Research Sites
13 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating brain-derived tau (BD-tau) as a blood-based biomarker for brain injury in acute ischemic stroke. Previous studies showed BD-tau levels correlate with brain injury and can predict functional outcomes, but the timing and progression of BD-tau changes after stroke onset are not fully understood. This study aims to track BD-tau levels hourly from admission up to 48 hours after stroke onset to better understand when BD-tau rises and plateaus. The study will include 100 patients diagnosed with acute ischemic stroke caused by a large- or medium-vessel occlusion within 9 hours of symptom onset. BD-tau and other brain injury markers like Neurofilament Light Chain will be measured every hour from admission to 48 hours after stroke onset using a blood test. Clinical data and neuroimaging results will be collected during hospitalization, and patients will be followed up clinically at 3 months. Participants will undergo frequent blood sampling to monitor BD-tau levels and have imaging assessments upon admission. Researchers will evaluate brain injury and infarct progression using CT and MRI scans, along with functional outcomes at 7 and 90 days after stroke. The study focuses on understanding the evolution of BD-tau as a marker of brain injury and its relationship with stroke progression and recovery over time.
CONDITIONS
Brief Title
PRecisiOn Medicine In StrokE: Evolution of Plasma Brain-Derived Tau in Acute Stroke
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of acute ischemic stroke
- Presentation within 9 hours of symptom onset
- Large- or medium-vessel occlusion confirmed by CT or MRI angiography
- At least 18 years of age
- Written informed consent
You will not qualify if you...
- CT or MRI showing intracranial hemorrhage upon admission
- History of ischemic stroke, subarachnoid hemorrhage, intracerebral hemorrhage, subdural hematoma, epidural hematoma, CNS tumor, meningitis, or encephalitis within the last three months
- Severe renal dysfunction (eGFR < 30ml/min/1.73m2)
- Dementia
- Pre-stroke disability with a modified Rankin Scale score greater than 1
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Diagnostic Evaluation
Duration - Up to 9 hours from symptom onset
Participants undergo assessment including neuroimaging and blood tests upon admission to confirm acute ischemic stroke due to large- or medium-vessel occlusion.
1 visit (in-person) upon admission
Monitoring
Duration - 48 hours
Participants have plasma BD-tau levels and other markers of brain injury assessed every hour from admission to 48 hours after stroke onset to monitor stroke progression.
Hourly blood sampling for up to 48 hours
Long-term Monitoring
Duration - Up to 3 months
Participants are followed clinically to assess functional outcomes at 7 days and 90 days after stroke onset.
2 follow-up visits at 7 days and 90 days after onset
Trial Site Locations
Total: 1 location
1
LMU University hospital, LMU Munich
Munich, Bavaria, Germany, 81377
Actively Recruiting
Loading map...
Research Team
S
Steffen Tiedt, MD PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data.
Götz Thomalla, Florent Boutitie, Henry Ma...
https://pubmed.ncbi.nlm.nih.gov/33176180Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials.
Mayank Goyal, Bijoy K Menon, Wim H van Zwam...
https://pubmed.ncbi.nlm.nih.gov/26898852Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.
William J Powers, Alejandro A Rabinstein, Teri Ackerson...
https://pubmed.ncbi.nlm.nih.gov/31662037European Stroke Organisation - European Society for Minimally Invasive Neurological Therapy expedited recommendation on indication for intravenous thrombolysis before mechanical thrombectomy in patients with acute ischaemic stroke and anterior circulation large vessel occlusion.
Guillaume Turc, Georgios Tsivgoulis, Heinrich J Audebert...
https://pubmed.ncbi.nlm.nih.gov/35300256European Stroke Organisation (ESO) - European Society for Minimally Invasive Neurological Therapy (ESMINT) Guidelines on Mechanical Thrombectomy in Acute Ischaemic StrokeEndorsed by Stroke Alliance for Europe (SAFE).
Guillaume Turc, Pervinder Bhogal, Urs Fischer...
https://pubmed.ncbi.nlm.nih.gov/31165090European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke.
Eivind Berge, William Whiteley, Heinrich Audebert...
https://pubmed.ncbi.nlm.nih.gov/33817340Clinical Imaging Factors Associated With Infarct Progression in Patients With Ischemic Stroke During Transfer for Mechanical Thrombectomy.
Gregoire Boulouis, Arne Lauer, Ahmer Khawdja Siddiqui...
https://pubmed.ncbi.nlm.nih.gov/28973081Predictors and clinical impact of infarct progression rate in the ESCAPE-NA1 trial.
Johanna Maria Ospel, Rosalie McDonough, Andrew M Demchuk...
https://pubmed.ncbi.nlm.nih.gov/34493575Hypoperfusion intensity ratio predicts infarct progression and functional outcome in the DEFUSE 2 Cohort.
Jean Marc Olivot, Michael Mlynash, Manabu Inoue...
https://pubmed.ncbi.nlm.nih.gov/24595591